Skip to product information
1 of 1

GeneBio Systems

PRPS1/2/PRPS1L1 Polyclonal Antibody

PRPS1/2/PRPS1L1 Polyclonal Antibody

SKU:E-AB-15944

Regular price £424.00 GBP
Regular price Sale price £424.00 GBP
Sale Sold out
Shipping calculated at checkout.

Size: 200μL

Storage: Store at -20℃ Valid for 12 months. Avoid freeze / thaw cycles.

Shipping: The product is shipped with ice pack,upon receipt,store it immediately at the temperature recommended.

Exp date: 12 months

Category ID_II: Primary Antibodies

Category ID_III: Polyclonal Antibodies

Abbreviation: PRPS1/2/1L1

Target Synonym: ARTS;DFN2;PRSI;CMTX5;DFNX1;PRS-I;PPRibP/PRSII/PRPS1;PRPS3;PRPSL;PRS-III

Research Areas: Cancer;Cell Biology;Epigenetics and Nuclear Signaling;Metabolism

Conjugation: Unconjugated

Host: Rabbit

Species reactivity: Human;Mouse

Application: WB;IHC

Isotype: IgG

Clonality: Polyclonal

Clone NO.:

UNIProt ID: P60891,P11908,P21108

Accession:

Background: PRPS (phosphoribosyl pyrophosphate synthetase) proteins catalyze the synthesis of phosphoribosyl pyrophosphate (PRPP). Three human PRPS isoforms exist and are encoded by three different genes. PRPS1 and PRPS2 (also known as PRS1 and PRS2, respectively) are ubiquitously expressed, while PRPS3 (also known as PRPS1L1) is specific to the testis. PRPP is an important substrate synthesized from MgATP and ribose-5-phosphate in a reaction that requires inorganic phosphate and magnesium as a cofactor. PRPP is essential in the synthesis of nearly all nucleotides, implying that PRPS1/2 play an important role in nucleotide biosynthesis and purine metabolism. A mutation in the gene encoding PRPS1 may result in PRPS superactivity, a disease characterized by gout and the overproduction of purine nucleotides, uric acid and PRPP. PRPS1 mutations can also lead to a reduction in PRPS1 activity resulting in ARTS syndrome or CMTX5 (Charcot-Marie-Tooth disease X-linked recessive type 5).

Concentration: 0.4 mg/mL

Immunogen: Synthetic peptide of human PRPS1/2/1L1

Buffer: PBS with 0.05% sodium azide and 50% glycerol, PH7.4

Purification method: Affinity purification

Dilution: WB 1:500-1:2000;IHC 1:25-1:100

Calculated MW: 35kDa

ObservedMW:

View full details